Everpar Advisors LLC Has $269,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Everpar Advisors LLC trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.8% in the fourth quarter, Holdings Channel reports. The firm owned 667 shares of the pharmaceutical company’s stock after selling 26 shares during the quarter. Everpar Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $269,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals during the third quarter worth approximately $25,000. Highline Wealth Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at $27,000. Dunhill Financial LLC raised its position in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $33,000. Finally, Truvestments Capital LLC bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $35,000. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on VRTX shares. Bank of America cut their price objective on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Canaccord Genuity Group raised their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research note on Wednesday, November 6th. Morgan Stanley boosted their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. UBS Group increased their price target on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Trading Up 1.2 %

VRTX stock opened at $422.00 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company’s fifty day simple moving average is $442.83 and its 200 day simple moving average is $466.48. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the previous year, the business earned $3.67 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.